Reprieve Cardiovascular, Inc., a clinical-stage company pioneering intelligent decongestion management therapy for acute decompensated heart failure (ADHF), announced the close of an oversubscribed $61 million Series B financing led by Deerfield Management and joined by Arboretum Ventures, Lightstone Ventures, Sante Ventures, Genesis Capital, Rex Health Ventures, and Cadence Capital, as well as an undisclosed strategic investor.

The financing combined equity investment with a debt facility to support the Company's growth. Proceeds from the Series B financing will support the rapid execution of the global FASTR II pivotal clinical trial, which has now enrolled its first patient, as well as key commercial readiness activities.